About AREVA Med
AREVA Med is an AREVA subsidiary specializing in the development of innovative new therapies to fight cancer.
How it works
Learn how the nuclear therapy works, what is lead-212 (212Pb), and about our ongoing research.
The Phase I clinical trials of lead-212 is currently taking place in the United States.
News & Materials
Read about the latest news and events, and download brochures and fact sheets.
Macrocyclics, part of AREVA Med, is the global leader in chelating agent technologies for medicine.
The Ecole Supérieure de Design de Troyes and AREVA Med sign a partnership agreement for the industrialization of new equipment to be used in the fight against cancerRead more
Roche and AREVA Med join forces in the fight against cancer and create a novel radio-immunotherapyRead more